These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 15800138)

  • 21. Donepezil for Alzheimer's disease.
    Benjamin B; Burns A
    Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donepezil: potential neuroprotective and disease-modifying effects.
    Jacobson SA; Sabbagh MN
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1363-9. PubMed ID: 18798705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.
    Matsuda O
    Int Psychogeriatr; 2007 Apr; 19(2):241-52. PubMed ID: 17005066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report.
    Na HR; Kim S; Choi SH; Yang DW; Bae HJ; Kim JE; Park MY; Shim YS; Kim BK; Kwon JC; Yoo BG; Kim BC; Lee JS
    Geriatr Gerontol Int; 2011 Jan; 11(1):90-7. PubMed ID: 20825496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
    Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease.
    Henigsberg N; Kalember P; Hrabać P; Rados M; Bajs M; Rados M; Kovavić Z; Loncar M; Madzar T
    Coll Antropol; 2011 Jan; 35 Suppl 1():159-62. PubMed ID: 21648328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types].
    Bachyns'ka NIu; Rozheliuk IF; Kholyn VO; Pishel' IM; Leonov IuI
    Wiad Lek; 2014; 67(2 Pt 2):161-5. PubMed ID: 25796815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
    Hanyu H; Tanaka Y; Sakurai H; Takasaki M; Abe K
    Neurosci Lett; 2002 Feb; 319(1):33-6. PubMed ID: 11814647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
    J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donepezil use in Alzheimer disease.
    Barner EL; Gray SL
    Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
    Tariot PN; Jakimovich L
    J Am Med Dir Assoc; 2003; 4(4):216-9. PubMed ID: 12837144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report.
    Zaidel L; Allen G; Cullum CM; Briggs RW; Hynan LS; Weiner MF; McColl R; Gopinath KS; McDonald E; Rubin CD
    J Alzheimers Dis; 2012; 31 Suppl 3(0 3):S221-6. PubMed ID: 22886013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
    Sugimoto H
    Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.